These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34769292)

  • 1. MicroRNA 132-3p Is Upregulated in Laron Syndrome Patients and Controls Longevity Gene Expression.
    Yaron-Saminsky D; Nagaraj K; Sarfstein R; Laron Z; Pasmanik-Chor M; Werner H
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of signaling pathways associated with cancer protection in Laron syndrome.
    Lapkina-Gendler L; Rotem I; Pasmanik-Chor M; Gurwitz D; Sarfstein R; Laron Z; Werner H
    Endocr Relat Cancer; 2016 May; 23(5):399-410. PubMed ID: 27090428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factors and aging: lessons from Laron syndrome.
    Werner H; Laron Z
    Front Endocrinol (Lausanne); 2023; 14():1291812. PubMed ID: 37941907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Olfactory Receptor Gene Product, OR5H2, Modulates Endometrial Cancer Cells Proliferation via Interaction with the IGF1 Signaling Pathway.
    Shibel R; Sarfstein R; Nagaraj K; Lapkina-Gendler L; Laron Z; Dixit M; Yakar S; Werner H
    Cells; 2021 Jun; 10(6):. PubMed ID: 34204736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of UDP-Glucuronosyltransferase 2B15 (UGT2B15) as a Target for IGF1 and Insulin Action.
    Sarfstein R; Nagaraj K; Parikh S; Levy C; Laron Z; Benayahu D; Werner H
    Cells; 2022 May; 11(10):. PubMed ID: 35626664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of nephronectin as a new target for IGF1 action.
    Sarfstein R; Lapkina-Gendler L; Nagaraj K; Laron Z; Werner H
    Eur J Cancer; 2020 Dec; 141():115-127. PubMed ID: 33130549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action.
    Nagaraj K; Lapkina-Gendler L; Sarfstein R; Gurwitz D; Pasmanik-Chor M; Laron Z; Yakar S; Werner H
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):1045-1050. PubMed ID: 29339473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation.
    Werner H; Sarfstein R; Nagaraj K; Laron Z
    Cells; 2020 Nov; 9(11):. PubMed ID: 33182502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome.
    Laron Z; Werner H
    Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37343154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GH-IGF1 axis and longevity. The paradigm of IGF1 deficiency.
    Laron Z
    Hormones (Athens); 2008; 7(1):24-7. PubMed ID: 18359741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term IGF1 Stimulation Leads to Cellular Senescence via Functional Interaction with the Thioredoxin-Interacting Protein, TXNIP.
    Nagaraj K; Sarfstein R; Laron Z; Werner H
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of IGFBPs in Laron syndrome-derived lymphoblastoid cell lines: Potential correlation with reduced cancer incidence.
    Somri L; Sarfstein R; Lapkina-Gendler L; Nagaraj K; Laron Z; Bach LA; Werner H
    Growth Horm IGF Res; 2018 Apr; 39():6-12. PubMed ID: 29208357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF-I deficiency, longevity and cancer protection of patients with Laron syndrome.
    Laron Z; Kauli R; Lapkina L; Werner H
    Mutat Res Rev Mutat Res; 2017; 772():123-133. PubMed ID: 28528685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Molecular Features of Laron Syndrome, A Genetic Disorder Protecting from Cancer.
    Janecka A; Kołodziej-Rzepa M; Biesaga B
    In Vivo; 2016; 30(4):375-81. PubMed ID: 27381597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-Wide Profiling of Laron Syndrome Patients Identifies Novel Cancer Protection Pathways.
    Werner H; Lapkina-Gendler L; Achlaug L; Nagaraj K; Somri L; Yaron-Saminsky D; Pasmanik-Chor M; Sarfstein R; Laron Z; Yakar S
    Cells; 2019 Jun; 8(6):. PubMed ID: 31208077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of lncRNA MEG3 rs941576 polymorphism, expression profile, and its related targets with the risk of obesity-related colorectal cancer: potential clinical insights.
    Senousy MA; Shaker OG; Ayeldeen G; Radwan AF
    Sci Rep; 2024 May; 14(1):10271. PubMed ID: 38704452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LESSONS FROM 50 YEARS OF STUDY OF LARON SYNDROME.
    Laron Z
    Endocr Pract; 2015 Dec; 21(12):1395-402. PubMed ID: 26401581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies.
    Steuerman R; Shevah O; Laron Z
    Eur J Endocrinol; 2011 Apr; 164(4):485-9. PubMed ID: 21292919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.
    Guo ST; Jiang CC; Wang GP; Li YP; Wang CY; Guo XY; Yang RH; Feng Y; Wang FH; Tseng HY; Thorne RF; Jin L; Zhang XD
    Oncogene; 2013 Apr; 32(15):1910-20. PubMed ID: 22710713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical defects resulting in growth hormone insensitivity.
    Wit JM; de Luca F
    Growth Horm IGF Res; 2016 Jun; 28():57-61. PubMed ID: 26670721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.